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 Acceptable: All control criteria (Table 1 below) are met
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treatment and possible side effectssev
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74 00.Table 1 Criteria defining acceptable asthma control.
Criterion Value or frequency*
Day-time symptoms o4 days/week
Night-time symptoms o1 night/week
Physical activity Normal
Exacerbations Mild, infrequent
Absence from work or school None
Use of short-acting b2-agonists o4 doses/week
FEV1 or PEF 485% of personal best
PEF diurnal variation (optional) o15%
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FEV: forced expiratory volume; PEF: peak expiratory flow.
- Follow-up includes monitoring of treatment side effects and
adherence.
- Treatment should be adjusted to level of control and current
long-term therapy.
 If control is unacceptable:
J Check: that the disease is asthma, adherence, correct use of
inhalation devices.
J Look for and treat: aggravating factors, concomitant disease,
specific clinical forms.
J Adjust long-term therapy (see Table 2 below) in steps of 1–3
months.
 If control is acceptable or optimal:
J Find the minimum effective treatment to maintain at least
acceptable and ideally optimal control. Each step should last 3
months.Table 2 Adjusting long-term therapy if control is unacceptable.
Current therapy New treatmenta
Option 1 Option 2
No ICS Average-dose ICS Average ICS
dose+AMb
Patients on ICS only
Low- or average-
dose ICS
Add AM Increase ICS dose
with or without AM
High-dose ICS Add AM
Patients on ICS and additional medication (AM)
Low dose of ICS (+1
AM)
Increase ICS dose
Average dose of ICS
(+1 AM)
Increase ICS dose Add second AM
with or without
increasing ICS dose
Heavy dose of ICS
(+1 AM)
Add second AM Oral
corticosteroidsc
Heavy dose of ICS
(+2 AMs)
Oral
corticosteroidsc
Add third AM
aThe choice between options will depend on symptom frequency and
respiratory function (particularly post-bronchodilator FEV1).
bAdditional medication (AM) covers long-acting b2-agonists, cysteinyl-
leukotriene receptor antagonists, theophylline and its derivatives
(bamiphylline).
cOral corticosteroids are rarely used in adolescents.- Frequency of follow-up visits (V) and lung function tests (LFTs)
according to the dose of inhaled corticosteroids (ICS) needed for
acceptable control (see Table 3 below)
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ICS dose V (months) LFT (months)High 3 3–6
Low or average 6 6–12
None 12 12 or +Low, average and high daily dose of ICS (mg/day) in adults.
Low dose Average dose High dose
Beclomethasonea o500 500–1000 41000
Budesonide o400 400–800 4800
Fluticasone o250 250–500 4500VARs and NEXXAIRsaDose should be halved for Q
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Objective
Asthma is a chronic condition. If follow-up is
regular, its management can be tuned to changes
in the course of the disease. The aim of follow-up is
to improve the patient’s quality of life and
prognosis. The aim of these guidelines is to address
the long-term medical follow-up of patients with
asthma (adults and adolescents only).Scope of the guidelinesThese guidelines: define follow-up criteria for patients with
asthma, assess the role of investigations during follow-up:
peak expiratory flow rate (PEF), lung function
tests (LFTs) including arterial blood gas, chest
radiograph, laboratory tests (blood eosinophils
and eosinophils in induced sputum),
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and death from asthma, propose methods for monitoring side effects and
adherence to treatment, propose ways of adjusting long-term therapy,
 propose a schedule for medical follow-up,
 describe specific aspects of follow-up in occupa-
tional asthma.
The guidelines do not cover: initial diagnosis of asthma,
 management of acute episodes (attacks, exacer-
bations and severe acute asthma),
 allergy-related aspects of management, notably
elimination of allergens and hyposensitisation,
 education for patients with asthma,
 efficacy of asthma treatments,
 the role of nitric oxide measurement in exhaled
air, examination of exhaled breath condensates,
or devices for ambulatory monitoring of forced
expiratory volume in 1 s (FEV1), as these tests
and devices are still experimental.Assessment method
The guidelines were produced using the method
described in Appendix B: a critical appraisal of the literature published
from January 1997 to December 2003, discussions within a multidisciplinary working
group (three meetings), comments by peer reviewers.
They were graded on the basis of the strength of
the evidence of the supporting studies
(Appendix B). If no grade is given, they are based
on agreement among professionals within the
working group after taking into account the
comments of peer reviewers.
Despite the extensive body of published data on
asthma, there are insufficient long-term data to
produce guidelines on follow-up criteria and sche-
dules that are supported by strong evidence. Some
of the classifications proposed here were therefore
determined on the basis of agreement among
professionals. Members of the working group wereSee
’ ’
Therapeutic education for patients with asthma –
ults and adolescents’’ (Anaes 2001).especially keen to provide healthcare professionals
with a practical decision-making tool suited to most
clinical situations, while emphasising that recom-
mendations can be adapted for specific circum-
stances.Asthma control: definition and criteria
Asthma control should be assessed over at least 1
week up to 3 months on the basis of clinical and
functional respiratory events, and their effects on
daily life. According to the working group and peer
reviewers,as
11follow-up of asthma patients should focus on
asthma control, asthma control should be assessed at each
follow-up visit.Control is graded in three levels: unacceptable,
acceptable and optimal. The criteria used to define
acceptable control are adapted from the Canadian
asthma consensus reporty (Table 1). They are based
on agreement among professionals and have not
been validated. Unacceptable control: One or more of the
criteria in Table 1 are not met. A change in
disease management is required. Acceptable control: All the criteria are met. This
is the minimum target level for all patients. Optimal control (i.e. best possible control):
J all the control criteria are either absent or
normal
J or, in a patient with acceptable control, the
best compromise has been achieved between
degree of control, acceptance of treatment
and possible side effects.yBou
thm
):S1Severity is also used to assess asthma. It refers to
the course of the disease over a long period (6–12
months). The severity criteria defined in the
guideline on therapeutic education for patients
with asthma are not given here, as follow-up should
focus on criteria for asthma control. Severity may
be defined simply as the minimum level of treat-
ment required for lasting disease control.let LP, Becker A, Be´rube´ D, Beveridge R, Ernst P. Canadian
a consensus report. Can Med Assoc J 1999;161(Suppl
–S61.
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Table 1 Criteria defining acceptable asthma control.
Criterion Mean value or frequency during control assessment
period (1 week–3 months)
Day-time symptoms o4 days/week
Night-time symptoms o1 night/week
Physical activity Normal
Exacerbations Mildy, infrequent
Absence from work or school None
Use of short-acting b2-agonists o4 doses/week
FEV1 or PEF 485% of personal best
PEF diurnal variation (optional) o15%
See definition in Appendix 3.
yMild exacerbation: exacerbation managed by patient, requiring only a temporary increase (for a few days) in daily use of
short-acting b2-agonists.
N. Roche et al.798Role of investigations during follow-up
Ambulatory peak expiratory flow (PEF)
measurement
PEF should be measured at follow-up visits. Results
should be expressed as a percentage of the
patient’s best value.
PEF monitoring at home using an ambulatory
device may be proposed:adfor patients at risk of severe acute asthma (see
definition in Appendix C) or death from asthma,
’ ’ to poor perceiver’’ patients, i.e. when the
patient’s symptoms are not proportional to the
degree of bronchial obstruction measured by PEF
or FEV1, when a high-risk period is anticipated (notably
the pollen season), during periods of unacceptable asthma control,
 when treatment is being changed.
However, it has not been demonstrated that
routine follow-up of all patients with home
measurement of PEF improves disease control.
PEF is a tool that can be used as part of the
patient’s therapeutic education to help them assess
their asthma and understand their disease.zLung function tests (LFTs)
LFTs should be carried out during follow-up of
patients with asthma (for recommended schedule,
see Section
’ ’
Follow-up schedule’’). Long-termz
’ ’
Therapeutic education for patients with asthma – adults and
olescents’’, Anaes 2001.therapy should not be interrupted before the LFTs
in order to be able to assess the bronchial
obstruction that persists despite therapy. Spirometry and in particular measurement of
FEV1, slow vital capacity and forced vital capacity
(FVC) are sufficient in most cases for assessing the
functional impact of asthma. These variables
should be measured before and after administra-
tion of fast-acting, short-duration bronchodila-
tors. Bronchial obstruction is given by relating
FEV1 after use of bronchodilator to the theoretical
value. In asthma that is difficult to control,
particularly in smokers, and while treatment is
being reduced, specialists may choose to assess
bronchial obstruction by measuring residual vo-
lume, small airway obstruction, and examining
the general shape of the forced expiration curve. Bronchial hyperresponsiveness (BHR) measure-
ment should not be used routinely for adjusting
treatment, particularly the dose of inhaled
corticosteroids (ICS). Although BHR may be useful
in dose adjustment (one level 2 study), follow-up
values cannot be measured routinely outside
specialist centres. Arterial blood gas measurement is indicated in
severe acute asthma. It is not indicated during
follow-up except in chronic respiratory failure.
Chest radiography
Chest radiography is used at initial diagnosis but
should not be a routine part of follow-up in patients
with asthma. It is indicated in severe exacerba-
tions, if there are problems with long-term disease
control or if complications are suspected (pneu-
mothorax, pneumonia).
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The course of asthma should not be monitored: by eosinophil counts or activation,
 by measuring eosinophils in induced sputum.
Although this may be useful in adjusting long-
term therapy (one level 2 study), it cannot be
monitored outside specialist centres.
Treatment follow-up
Follow-up of side effects Long-term b2-agonists or anticholinergics
No specific form of follow-up is recommended
within the limits given in the French marketing
authorisations of b2-agonists or anticholinergics. Theophylline
Patients should be monitored at each visit,
especially clinically, as theophylline has a narrow
therapeutic margin, and drug interactions and
side effects are common. If side effects occur or
the drug is felt to be clinically ineffective, blood
theophylline concentration should be measured.
Measurements after treatment has started may
be routine and should be so if there are risk
factors for side effects, e.g.
J young children,
J the elderly,
J acute heart failure (reduce the dose because
of risk of overdose),
J coronary insufficiency,
J obesity (adjust the dose in relation to ideal
weight),
J hyperthyroidism,
J impaired liver function,
J history of seizures,
J prolonged fever (438 1C) lasting more than
24 h, particularly in young children (halve the
dose because of risk of overdose),
J concomitant therapy likely to increase blood
theophylline concentration, or discontinua-
tion of drugs likely to reduce it.yy Dru
allo
pe
my
Dru
dis
con
ph
gri
Th
thegs that increase blood theophylline concentration are
purinol, cimetidine, fluconazole, ciprofloxacin, norfloxacin,
floxacin, fluvoxamine, clarithromycin, erythromycin, josa-
cin, roxithromycin, mexiletine, pentoxifylline, stiripentol.
gs that reduce blood theophylline concentration (i.e.
continuation is likely to increase blood theophylline
centration) are enzyme inducers such as carbamazepine,
enobarbital, phenytoin, primidone, rifampicin, rifabutin,
seofulvin, ritonavir, lopinavir, nelfinavir.
e range of active ingredients likely to interfere with
ophylline metabolism will vary as new drugs are licensed.anLong-term ICS
During follow-up
J look for local side effects (candidiasis of the
mouth, dysphonia) and skin fragility,
J monitor growth in adolescents,
J refer patients with a history or risk of
cataracts or glaucoma to an ophthalmologist.
Extended prescription or sudden withdrawal
of high doses of ICS should be avoided if
possible.
No specific monitoring of bone effects from
ICS is recommended when doses are low or
average or when treatment lasts o5 years
(Grade A). However, the safety of high ICS
doses for periods 45 years and in patients
with other risk factors for osteopenia has not
been assessed.
Unexplained asthenia in patients taking long-
term, high-dose ICS should prompt investiga-
tion for adrenal insufficiency or Cushing’s
syndrome; rare cases of acute adrenal insuffi-
ciency have been described, mainly in
children.zSee
d ad Long-term oral corticosteroids
Patients should be monitored as recommended in
the French marketing authorisations of the drugs
concerned. Leukotriene receptor antagonists
No specific form of follow-up is recommended
within the limits given in the French marketing
authorisation of the drugs concerned.
Monitoring treatment adherence
Patients should be asked regularly about the
medications they are taking, but the risk of
overestimating adherence persists. This risk can
be reduced by telling patients that it is in their
interest to report as accurately as possible what
medication they have taken so that treatment can
be adjusted to their real needs (Grade C). They can
be asked to keep a diary during the week or weeks
preceding each visit (including a record of medica-
tion and asthma control criteria).
Patients with known or suspected lack of ad-
herence may be motivated by scheduling more
frequent follow-up sessions. Structured therapeutic
education may help.z
Adjusting treatment during follow-up
These guidelines do not cover the initial manage-
ment strategy or management of acute events’ ’
Therapeutic education for patients with asthma – adults
olescents’’, Anaes 2001.
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Table 2 Low, average and high daily dose of ICS (mg/d) in adults.
Low dose Average dose High dose
Beclomethasone o500 500–1000 41000
Budesonide o400 400–800 4800
Fluticasone o250 250–500 4500
Dose should be halved for QVARs and NEXXAIRs.
N. Roche et al.800(attacks, exacerbations, severe acute asthma).
Treatment should be adjusted to: degree of asthma control,
 current long-term therapy.
If asthma control is unacceptable (see Section
Definition and Criteria)
Management should be improved in three stages, as
follows: Stage 1: Check that:
J the disease is actually asthma; this is espe-
cially relevant if bronchial obstruction cannot
be reversed,
J adherence to current treatment is satisfac-
tory,
J the patient is using inhalation devices cor-
rectly. Stage 2: Look for and treat:
J aggravating factors such as exposure to aller-
gens, rhinitis, active or passive smoking,
medication (e.g. b-blockers), exposure to air
pollution, ENT infection, gastro-oesophageal
reflux,
J concomitant disease such as COPD or heart
failure,
J rare specific clinical forms such as
allergic bronchopulmonary aspergillosis,
Churg–Strauss vasculitis. Stage 3: Adjust long-term therapy (see Table 3)
to medication taken to date, particularly to
current ICS dose (see Table 2).
J Patients not taking long-term therapy: An ICS
should be started at the average dose. If
symptoms are frequent and FEV1 is signifi-
cantly reduced, give additional medication
(AM) (long-acting b2-agonists, cysteinyl-leuko-
triene receptor antagonists or theophylline
and its derivatives).
J Patients on low- or average-dose ICS: Give AM
or increase the dose of ICS. If symptoms are
frequent and FEV1 is significantly reduced,
increase ICS dose and give AM.
J Patients on high-dose ICS: Give AM.J Patients on low-dose ICS with AM: Increase
dose of ICS.
J Patients on average-dose ICS with AM: In-
crease dose of ICS or add a second AM. If
symptoms are frequent and FEV1 is signifi-
cantly reduced, increase ICS dose and give
AM.
J Patients on high-dose ICS with AM: Give a
second AM. If symptoms are frequent and FEV1
is significantly reduced, suggest oral corticos-
teroids.
J Patients on high-dose ICS with two AMs: Start
oral corticosteroids, probably as long-term
therapy, or add a third AM.Stage 3 guidelines are summarised in Table 3.
Oral corticosteroids should be avoided if possi-
ble, particularly in adolescents. If it is difficult to
decide on the best treatment, consult a specialist.
If symptoms are frequent and/or FEV1 is con-
siderably reduced, an increase in long-term ther-
apy may be combined initially with short-term oral
corticosteroids (o15 days at a dose of 0.5–1mg/
kg/d) to achieve faster control.
Each stage of treatment lasts from 1 to 3 months
depending on clinical and functional response. If
acceptable control is not achieved despite maximal
therapy, patients should be referred to a specialist.
If asthma control is acceptable or optimal
Once control has been achieved, the minimum
effective therapy to maintain acceptable—and
ideally optimal—control should be found. In ado-
lescents, the younger the patient, the more
desirable it is to achieve optimal control.
Generally, long-term therapy should be reduced
in 3-month steps but no studies have compared
different step durations. ICS can be reduced in
25–50% steps. There are no data to support a
specific program for discontinuing AM.
If there are any side effects with long-term
therapy or if the patient is at risk of side effects,
reassess benefit/risk ratio more often.
In patients who receive long-term oral corticos-
teroids from the start, the dose should be reduced
ARTICLE IN PRESS
Table 3 Adjusting long-term therapy (Stage 3).
Current therapy New treatment
Option 1 Option 2
No ICS Average-dose ICS Average ICS dose+AM
Patients on ICS only
Low or Average-dose ICS Add AM Increase ICS dose with or without
AM
High dose ICS Add AM
Patients on ICS and additional
medication (AM)y
Low dose of ICS (+1 AM) Increase ICS dose
Average dose of ICS (+1 AM) Increase ICS dose Add 2nd AM with or without
increasing ICS dose
Heavy dose of ICS (+1 AM) Add second AM Oral corticosteroidsz
Heavy dose of ICS (+2 AMs) Oral corticosteroidsz Add third AM
The choice between options will depend on symptom frequency and function (particularly post-bronchodilator FEV1).
yAdditional medication (AM) covers long-acting b2-agonists, cysteinyl-leukotriene receptor antagonists, theophylline and its
derivatives (bamiphylline).
zOral corticosteroids are rarely used in adolescents.
Table 4 Frequency of visits and LFT during follow-up depending on ICS dose.
ICS dose Minimum follow-up (months) Optimal follow-up (months)
Visits LFT Visit LFT
High 3y 6 3 3
Low or average 6 12 6 6
None 12 12 or + 12 12
Visit with clinical examination including determination of PEF.
yAn appointment with a specialist should be considered.
Medical follow-up of patients with asthma—Adults and adolescents 801very gradually, and concomitant high-dose ICS and
long-acting b2-agonists should be given. Each step
may last about 3 months, and complete withdrawal
may take several years.Follow-up schedule
The proposed follow-up schedule should be ad-
justed to each individual patient. For example it
does not take account of therapeutic education
sessions, visits because of an intercurrent event or
possible increased frequency of visits during initial
management or changes in therapy. When control is acceptable or optimal
The minimum and optimum frequency of visits
when control is acceptable or optimal is given in
Table 4. When control is unacceptable
J Patient on short-term oral corticosteroids:Visit with at least a clinical examination
including determination of PEF, and ideally
LFT, during the week following withdrawal of
oral corticosteroids and 1 month later. An
appointment with a specialist should be
considered.
J Patient not taking short-term oral corticos-
teroids: Visit with at least a clinical examina-
tion including determination of PEF, and
ideally LFT, 1–3 months after change in
therapy. In the presence of risk factors
Follow-up frequency should be increased in
patients at risk of severe acute asthma or death
from asthma and in patients experiencing fre-
quent exacerbations, i.e. asthma that is difficult
to control. These patients may benefit from
J scheduled visits after they leave hospital,
J structured therapeutic education,
J a rigorous search for and elimination of trigger
factors (allergens, tobacco, domestic and
industrial toxins),
ARTICLE IN PRESS
N. Roche et al.802J possibly a home visit from a domestic envir-
onment adviser.The case of occupational asthma
Follow-up of occupational asthma involves both
medical and socioprofessional aspects, which are
complementary and inseparable.
Patients who are no longer exposed to the risk
should be followed-up medically for a long time, as
symptoms and non-specific bronchial hyperrespon-
siveness persist in 450% of cases (Grade C).
Work-related (determination of ability to work) and
medical/legal aspects (compensation) are further
reasons for objective assessment of the disease by
spirometry and methacholine challenge testing.
Elimination or reduction of exposure to risk,
continued employment and/or maintenance of
income requires a support network around the
patient–doctors, social workers, and advisers from
work reclassification services. The main tools
that can be used are notification of occupational
disease, a request for classification as a handi-
capped worker and visiting the occupational phy-
sician before going back to work.Acknowledgements
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ParisAppendix B. Assessment method
The Anaes method for producing these clinical
practice guidelines comprised the following steps:
Defining the scope of the guidelines (Steering
committee). Anaes invited representatives from
learned societies concerned by the topic to take
part in a steering committee whose job was to
define the scope of the guidelines, to review
previous work on the subject and to nominate
professionals to take part in a working group or act
as peer reviewers.
Literature search (Documentation Department
of Anaes): See below
Drafting the guidelines (Working group). The
Anaes project manager formed a working group of
19 professionals from a number of disciplines,
working in public or private practice, from all over
the country. The chair of the working group
coordinated the production of the guidelines with
the help of the project manager whose job was tommandations pour la pratique
ur leur re´alisation en France –ensure conformity with the methodological princi-
ples of guideline production. Two members of the
working group identified, selected, and analysed
relevant studies (from a literature search per-
formed by the Anaes Documentation Department)
and wrote a draft report. This draft report was
discussed by the working group over three meetings
and amended in the light of comments from other
members of the working group and from peer
reviewers. Proposals for future studies and action
were made.
External validation (Peer reviewers). Peer
reviewers were appointed according to the same
criteria as working group members. They were
consulted by post after the second working group
meeting, primarily with regard to the readability
and applicability of the guidelines (scores from 1 to
9). The Anaes project manager summarised their
comments and submitted them to the working
group prior to the third meeting. Peer reviewers
were asked to undersign the final document.
Internal validation (Evaluation Section of the
Anaes Scientific Council). Two members of the
Council acted as referees reporting to the Council,
together with the Anaes report manager. The
working group finalised the guidelines with due
regard to the Council’s suggestions. Literature search and analysis (general pro-
cedure)
The scope of the literature search was defined by
the steering committee and the project manager.
The search was carried out by the Anaes
Documentation Department and focused on
searching
J medical and scientific databases over an
appropriate period, with special emphasis on
retrieving clinical practice guidelines, con-
sensus conferences, articles on medical
decision-making, systematic reviews, meta-
analyses and other assessments already pub-
lished nationally or internationally (articles in
French or English),
J specific and/or financial/economic databases,
if necessary,
J all relevant websites (government agencies,
professional societies, etc.),
J the grey literature (documents not identified
through the usual information distribution
circuits),
J legislative and regulatory texts.
Further references were obtained from citations
in the articles retrieved above and from working
group members’ and peer reviewers’ own refer-
ence sources. The search was updated until the
project was completed.
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Table 5 Grading of guidelines.
Level of published scientific evidence Grade
Level 1
Randomised controlled trials of high power A: Established scientific evidence
Meta-analyses of randomised controlled trials
Decision analyses based on properly conducted studies
Level 2
Randomised controlled trials of low power B: Presumption of scientific
foundation
Properly conducted non-randomised controlled trials
Cohort studies
Level 3
Case-control studies
Level 4
Comparative studies with major bias C: Low level of evidence
Retrospective studies
Case series
Medical follow-up of patients with asthma—Adults and adolescents 805The articles selected were analysed according to
the principles of a critical appraisal of the
literature, using a checklist, to allocate a level of
scientific evidence to each study. Whenever possi-
ble, the working group based their guidelines on
this review of the literature. Guidelines were
graded from A to C as shown in Table 5 depending
on the level of the evidence of the supporting
studies. If no grading is given, they are based on
agreement among professionals. Specifics of the literature search for this
study
The following databases were searched
J Medline (National Library of Medicine, United
States)
J Embase (Elsevier, Netherlands)
J Pascal (CNRS-INIST, France)
J Cochrane Library (Great Britain)
J National Guideline Clearinghouse (United
States)
J HTA Database (International network of agen-
cies for health technology assessment—INAH-
TA)
J BDSP (Public health database, Rennes)The strategy for searching the Medline, Embase
and Pascal databases is given in Table 6. The search
terms were either thesaurus terms (MeSH descrip-
tors for Medline) or terms from titles or abstract
(free text).Appendix C. Definitions
Asthma attack: A paroxystic episode of symptoms
lasting a short time (p1 day).
Exacerbation: An episode of gradual deteriora-
tion, over several days, in one or more clinical
signs, and functional parameters of bronchial
obstruction. It is classed as severe if oral corticos-
teroids are needed or if PEF falls by more than 30%
below baseline values for 2 consecutive days.
Severe acute asthma: defined in adults by one of
the following signs: pulse 4110/min, respiratory rate X25/min,
 inability to finish sentences in a single respiratory
cycle,
 PEF p50% of theoretical value or patient’s best-
known value,
 bradycardia,
 hypotension,
 no sounds audible on auscultation,
 cyanosis,
 confusion or coma,
 exhaustion.
 Risk factors for severe acute asthma and death
by asthma (level of evidence 3):
J poor socioeconomic circumstances,
J adolescent or elderly subjects,
J history of
’ ’
nearly fatal’’ asthma or hospitali-
sation in intensive care with asthma,
J FEV1o40% of theoretical value,
J 450% reversibility on b2-agonist treatment,
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Table 6 Search strategy.
Type of study/subject Terms used Search period
Guidelines 1997–2003
Stage 1 Asthma
AND Stage 2 Guideline* OR Practice guideline OR Health
planning guideline OR Guideline [title] OR
Consensus development conference OR
Consensus development conference, NIH
OR Consensus conference[title] OR
Consensus statement[title]
Meta-analyses, literature reviews 1997–2003
Stage 1
AND Stage 3 Meta analysis OR Review literature OR
Literature review OR Systematic review
Management during follow-up 1997–2003
Stage 1
AND Stage 4 Management (in title) OR [(Therapy OR
Drug therapy OR Rehabilitation) AND Follow
up OR Follow-up studies OR Follow*]
Care programmes for patients
with asthma
1997–2003
Stage 1
AND Stage 5 Self management program
Lung function tests 1997–2003
Stage 1
AND Stage 6 (Peak expiratory flow rate OR Expiratory
flow rate OR Forced expiratory flow rates
OR Forced expiratory volume OR Bronchial
hyperreactivity OR Respiratory function
tests OR Respiratory sound* OR Spirometry )
AND (Follow up OR Follow-up studies OR
Follow*)
Physical examination during
follow-up
1997–2003
Stage 1
AND Stage 6 (Physical examination OR Clinical
examination) AND (Follow up OR Follow-up
studies OR Follow*)
Radiography 1997–2003
Stage 1
AND Stage 7 Mass chest X-ray
Patient compliance 2000–2003
Stage 1
AND Stage 8 Patient compliance OR Patient acceptance
of health care OR Patient education
Asthma control during follow-up 1997–2003
Stage 9 Asthma control
Quality of life questionnaires 1997–2003
Stage 1
AND Stage 10 Quality of life AND Questionnaire
OR
Juniper E (as author)
Rhinitis 1997–2003
N. Roche et al.806
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Table 6 (continued )
Type of study/subject Terms used Search period
Stage 1
AND Stage 11 Rhinitis AND (Follow up OR Follow-up
studies OR Follow*)
French literature 1993–2003
Stage 1 Asthma*
AND Stage 12 Control* OR Suivi OR Surveillance
Total number of references found 2957
Total number of articles studied 696
Number of articles cited 296
* Truncature
Medical follow-up of patients with asthma—Adults and adolescents 807J frequent visits to accident and emergency or
GP or repeated hospital admissions,
J elevated blood eosinophils (41000/mm3),
J patients who are
’ ’
poor perceivers’’ of their
degree of bronchial obstruction,
J smoking 420 packs/year,
J poor adherence and/or denial of disease,
J use of three (or more) asthma medications,
J corticosteroid therapy stopped in last 3
months.References analysed for guideline
production
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